Departamento de Dermatologia - FM/MDT
URI Permanente desta comunidade
O Departamento de Dermatologia da Faculdade de Medicina da Universidade de São Paulo (FMUSP) objetiva capacitar o aluno para que reconheça as principais doenças dermatológicas por meio de exame semiológico, com aulas práticas e teóricas. Oferece programas de Pós-Graduação stricto sensu, em nível de mestrado e doutorado, voltados à capacitação de docentes e pesquisadores na área de dermatologia.
As linhas de pesquisa incluem: dermatologia infantil; dermatoses infecciosas e parasitárias; imunodermatologia, Imunomodulação experimental; imunopatologia da infecção pelo HIV; imunopatologia das imunodeficiências primárias, imunopatologia das imunodeficiências secundárias, infecciosas ou metabólicas; oncologia cutânea; terapêutica dermatológica clínica e cirúrgica.
Site oficial: http://www.dermatousp.com.br/
As linhas de pesquisa incluem: dermatologia infantil; dermatoses infecciosas e parasitárias; imunodermatologia, Imunomodulação experimental; imunopatologia da infecção pelo HIV; imunopatologia das imunodeficiências primárias, imunopatologia das imunodeficiências secundárias, infecciosas ou metabólicas; oncologia cutânea; terapêutica dermatológica clínica e cirúrgica.
Site oficial: http://www.dermatousp.com.br/
Índice h
Scopus: 47
Navegar
Coleções desta Comunidade
- Departamento de Dermatologia - FM/MDT
- Departamento de Dermatologia - FM/MDT
- Departamento de Dermatologia - FM/MDT
Submissões Recentes
100 anos de dermatologia USP
(2016)
Manifestações orais na doença inflamatória intestinal
(2015) NICO, Marcello Menta Simonsen; BOLOGNA, Sheyla Batista; LORENçO, Silvia Vanessa
Prefácio
(2016) RIVITTI, Evandro A.
Prefácio
(2016) RIVITTI, Evandro A.
Avant Propos
(2016) FESTA NETO, Cyro; NICO, Marcello Menta S.
Doenças tropicais: paracoccidioidomicose
(2022) BENARD, Gil; CAVALCANTE, Ricardo de Souza; DUARTE NETO, Amaro Nunes; LOURES, Flávio Vieria; CALICH, Vera Lúcia Garcia
Aids: complicações neurológicas
(2021) BERMúDEZ, José Ernesto Vidal; CASSEB, Jorge Simão do Rosário; SANTOS, Tatiane Assone dos; OLIVEIRA, Augusto Cesar Penalva de
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study
(2024) EYERICH, Kilian; GOODERHAM, Melinda J.; SILVESTRE, Juan Francisco; SHUMACK, Stephen P.; MENDES-BASTOS, Pedro; AOKI, Valeria; ORTONCELLI, Michela; SILVERBERG, Jonathan I.; TEIXEIRA, Henrique D.; CHEN, Shirley H.; CALIMLIM, Brian M.; TAKEMOTO, Shunya; SANCHO, Cristina; FRITZ, Bjoern; IRVINE, Alan D.
Background: Atopic dermatitis (AD), a relapsing, inflammatory skin disease, is associated with pruritus that can negatively affect patients' quality of life. Understanding the burden of AD is critical for informing and tailoring treatment and disease management to improve patient outcomes. This study characterized global treatment patterns and the clinical, psychosocial and economic burden of moderate- to-severe AD. Methods: MEASURE- AD was a cross-sectional 28-country study in patients with physician-confirmed moderate- to-severe AD who were either receiving or eligible for systemic therapy for AD. Patients =12 years were enrolled between December 2019 and December 2020 while attending routine office or clinic visit. Primary out-comes included Worst Pruritus Numeric Rating Scale (WP- NRS; range: 0- 10) and Dermatology Life Quality Index (DLQI; range: 0- 30) and Childrens DLQI (CDLQI; range: 0- 30). Secondary outcomes included physician-and patient-reported clinical, psychosocial and economic burden.Results: Of the 1591 patients enrolled, 1558 (1434 adults and 124 adolescents) ful-filled all patient selection criteria and were included in this analysis. Almost all patients (98.4%) in the total population were using AD medications and more than half (56%) were receiving systemic medication (15% systemic monotherapy). The most used systemic therapies were dupilumab (56.3%), systemic glucocorticoids (18.1%) and methotrexate (16.2%). Mean WP- NRS was 5.3 in the total population, and most patients (= 55%) reported moderate- to-severe pruritus (WP-NRS = 4). Mean DLQI was 10.8 and mean CDLQI was 9.6. Secondary endpoints demonstrated substantial clinical, psychosocial, and economic burden of disease. Subgroup analysis demonstrated that patients receiving systemic therapy had lower disease burden than those not taking systemic medications.Conclusions: While systemic therapy lowers overall disease burden, patients with moderate- to-severe AD continue to have substantial multidimensional disease bur-den and uncontrolled disease. Overall, there is a need for effective disease management, including effective treatments that improve patients' psychosocial outcomes and reduce the economic burden of AD.
Delusional infestation treated with risperidone: a series of 27 patients
(2024) GUEDES, Nycolle L. K. O.; DWAN, Alexandre J.; GERLERO, Paula; NICO, Marcello M. S.
Background Patients with delusional infestation (DI) frequently refuse to be treated with psychoactive drugs. In the past, pimozide was commonly used as a first-line agent but is now prescribed more rarely. Risperidone was first used to treat DI in 1995. A recent review identified 12 studies that evaluated the use of risperidone in 43 patients with DI.Objectives To study the characteristics of and therapeutic results in patients with DI treated with risperidone at a university medical centre in Sao Paulo, Brazil.Methods We performed a retrospective study of patients with DI treated with risperidone at a dermatological university clinic since 2016. Records were reviewed for personal data and findings related to treatment.Results Twenty-seven patients were studied (20 women and 7 men). The maintenance dose of risperidone varied from 1 mg three times weekly to 8 mg daily. Control of symptoms was achieved in the majority of patients. A reduction in dosage due to side-effects was seen in four patients; risperidone had to be switched to another antipsychotic in three cases, despite a good response. Only one patient did not respond to risperidone.Conclusions Risperidone is an effective, well-tolerated and safe treatment for delusional parasitosis. Adequate follow-up is mandatory in order to obtain long-term control of symptoms. Patients with delusional infestation (DI) frequently refuse to be treated with psychoactive drugs. Risperidone was first used to treat DI in 1995. A recent review identified 12 studies evaluating risperidone, with a total of 43 patients with DI. We studied the characteristics and therapeutic results in 27 patients with DI treated with risperidone in a university medical centre in Sao Paulo, Brazil. Control of symptoms was achieved in the majority. Risperidone is an effective, well-tolerated and safe treatment for DI. Adequate follow-up is mandatory to obtain long-term control of symptoms.
Histopathologic findings in ointment pseudo-cheilitis: An alert to dermatopathologists
(2024) NICO, Marcello Menta Simonsen; SIERRA, Jose Ollague; MOYA, Fernanda Goncalves; LOURENCO, Silvia Vanessa
Ointment pseudo-cheilitis is a recently recognized distinctive type of self-induced cheilitis. Lesions consist of a variable amount of crusts adhered to the vermilion. These crusts consist of dried saliva and dead cells mixed with applied medications attached to the lip surface. Patients are typically severely anxious or depressed; the condition impacts quality of life. Ointment pseudo-cheilitis is frequently misdiagnosed as exfoliative cheilitis or cheilitis glandularis. Biopsy reports are often non-revealing because there are no established histopathological criteria for this disease, and clinicians usually do not formulate the correct diagnostic hypothesis. Here, we present the histopathological findings of four cases of ointment pseudo-cheilitis. The most consistent finding was the presence of laminated parakeratotic material detached from the epithelium in biopsies that are devoid of other significant diagnostic changes. This material at the lip surface possibly represents physiologic labial desquamation mixed with dried saliva and applied medication. With this report, we intend to alert dermatopathologists to the diagnosis of ointment pseudo-cheilitis if they receive biopsies from patients who present clinically exuberant labial lesions that show only minimal histopathological changes.